Study S003302

An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Tablet Formulation (F2) of ECC5004 and Food Effects on F1 and F2 of ECC5004 in Healthy Participants

ClinicalTrials.gov record

Registration

Registration: NCT06268145
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 14
Start: 2024-02-06
Primary completion: 2024-03-29
Lead sponsor: Eccogene
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:ECC5004
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

ECC5004 PK parameters: AUC0-tlast [Up to day 6]
ECC5004 PK parameters: AUC0-inf [Up to day 6]
ECC5004 PK parameters: Cmax [Up to day 6]
ECC5004 PK parameters: tmax [Up to day 6]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.